Table of Contents Author Guidelines Submit a Manuscript
Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 278035, 14 pages
http://dx.doi.org/10.1155/2013/278035
Research Article

Indoleamine 2,3-Dioxygenase: Expressing Cells in Inflammatory Bowel Disease—A Cross-Sectional Study

1Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, Tlalpan, 14000 Mexico City, DF, Mexico
2Department of Gastroenterology, Inflammatory Bowel Disease Clinic, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Vasco de Quiroga No. 15, Colonia Sección XVI, Tlalpan, 14000 Mexico City, DF, Mexico

Received 12 June 2013; Accepted 29 August 2013

Academic Editor: Piotr Kraj

Copyright © 2013 Janette Furuzawa-Carballeda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. K. Podolsky, “Inflammatory bowel disease,” The New England Journal of Medicine, vol. 347, no. 6, pp. 417–429, 2002. View at Publisher · View at Google Scholar · View at Scopus
  2. M. A. Ciorba, “Indoleamine 2, 3 dioxygenase in intestinal disease,” Current Opinion in Gastroenterology, vol. 29, pp. 146–152, 2013. View at Publisher · View at Google Scholar
  3. D. H. Munn, M. D. Sharma, and A. L. Mellor, “Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells,” Journal of Immunology, vol. 172, no. 7, pp. 4100–4110, 2004. View at Google Scholar · View at Scopus
  4. A. L. Mellor, D. B. Keskin, T. Johnson, P. Chandler, and D. H. Munn, “Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses,” Journal of Immunology, vol. 168, no. 8, pp. 3771–3776, 2002. View at Google Scholar · View at Scopus
  5. F. Fallarino, C. Vacca, C. Orabona et al., “Functional expression of indoleamine 2,3-dioxygenase by murine CD8α+ dendritic cells,” International Immunology, vol. 14, no. 1, pp. 65–68, 2002. View at Google Scholar · View at Scopus
  6. L. Zhu, F. Ji, Y. Wang et al., “Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition,” Journal of Immunology, vol. 177, no. 11, pp. 8226–8233, 2006. View at Google Scholar · View at Scopus
  7. A. L. Mellor and D. H. Munn, “Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?” Immunology Today, vol. 20, no. 10, pp. 469–473, 1999. View at Publisher · View at Google Scholar · View at Scopus
  8. P. J. Royer, M. Emara, C. Yang et al., “The mannose receptor mediates the uptake of diverse native allergens by dendritic cells and determines allergen-induced T cell polarization through modulation of IDO activity,” The Journal of Immunology, vol. 185, no. 3, pp. 1522–1531, 2010. View at Publisher · View at Google Scholar
  9. A. L. Mellor and D. H. Munn, “Tryptophan catabolism and regulation of adaptive immunity,” Journal of Immunology, vol. 170, no. 12, pp. 5809–5813, 2003. View at Google Scholar · View at Scopus
  10. A. L. Mellor and D. H. Munn, “IDO expression by dendritic cells: tolerance and tryptophan catabolism,” Nature Reviews Immunology, vol. 4, no. 10, pp. 762–774, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. U. Grohmann, C. Volpi, F. Fallarino et al., “Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy,” Nature Medicine, vol. 13, no. 5, pp. 579–586, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. P. Puccetti and F. Fallarino, “Generation of T cell regulatory activity by plasmacytoid dendritic cells and tryptophan catabolism,” Blood Cells, Molecules, and Diseases, vol. 40, no. 1, pp. 101–105, 2008. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Fujino, A. Andoh, S. Bamba et al., “Increased expression of interleukin 17 in inflammatory bowel disease,” Gut, vol. 52, no. 1, pp. 65–70, 2003. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Fonseca-Camarillo, E. Mendivil-Rangel, J. Furuzawa-Carballeda, and J. K. Yamamoto-Furusho, “Interleukin 17 gene and protein expression are increased in patients with ulcerative colitis,” Inflammatory Bowel Diseases, vol. 17, no. 10, pp. E135–E136, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. G. Hundorfean, M. F. Neurath, and J. Mudter, “Functional relevance of T helper 17 (Th17) cells and the IL-17 cytokine family in inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 18, no. 1, pp. 180–186, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. S. M. Sa, P. A. Valdez, J. Wu et al., “The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis,” Journal of Immunology, vol. 178, no. 4, pp. 2229–2240, 2007. View at Google Scholar
  17. L. R. Sutherland, F. Martin, S. Greer et al., “5-aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis,” Gastroenterology, vol. 92, no. 6, pp. 1894–1898, 1987. View at Google Scholar · View at Scopus
  18. W. R. Best, J. M. Becktel, J. W. Singleton, and F. Kern Jr., “Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study,” Gastroenterology, vol. 70, no. 3, pp. 439–444, 1976. View at Google Scholar · View at Scopus
  19. M. B. Frenz, P. Dunckley, L. Camporota, D. P. Jewell, and S. P. L. Travis, “Comparison between prospective and retrospective evaluation of Crohn's disease activity index,” American Journal of Gastroenterology, vol. 100, no. 5, pp. 1117–1120, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. I. Simera, D. Moher, J. Hoey, K. F. Schulz, and D. G. Altman, “A catalogue of reporting guidelines for health research,” European Journal of Clinical Investigation, vol. 40, no. 1, pp. 35–53, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. I. J. Fuss, “Is the Th1/Th2 paradigm of immune regulation applicable to IBD?” Inflammatory Bowel Diseases, vol. 14, supplement 2, pp. S110–S112, 2008. View at Google Scholar · View at Scopus
  22. T. Olsen, R. Rismo, G. Cui, R. Goll, I. Christiansen, and J. Florholmen, “TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation,” Cytokine, vol. 56, no. 3, pp. 633–640, 2011. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Zanoni and F. Granucci, “The regulatory role of dendritic cells in the induction and maintenance of T-cell tolerance,” Autoimmunity, vol. 44, no. 1, pp. 23–32, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. D. Favre, J. Mold, P. W. Hunt et al., “Tryptophan catabolism by indoleamine 2, 3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease,” Science Translational Medicine, vol. 2, no. 32, pp. 32–36, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Gasparri, E. Jachetti, B. Colombo et al., “Critical role of indoleamine 2,3-dioxygenase in tumor resistance to repeated treatments with targeted IFNγ,” Molecular Cancer Therapeutics, vol. 7, no. 12, pp. 3859–3866, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. J. Furuzawa-Carballeda, G. Lima, N. Uribe-Uribe et al., “High levels of IDO-expressing CD16+ peripheral cells, and tregs in graft biopsies from kidney transplant recipients under belatacept treatment,” Transplantation Proceedings, vol. 42, no. 9, pp. 3489–3496, 2010. View at Publisher · View at Google Scholar · View at Scopus
  27. J. Furuzawa-Carballeda, G. Lima, J. Jakez-Ocampo, and L. Llorente, “Indoleamine 2,3-dioxygenase-expressing peripheral cells in rheumatoid arthritis and systemic lupus erythematosus: a cross-sectional study,” European Journal of Clinical Investigation, vol. 41, no. 10, pp. 1037–1046, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. Correale and A. Villa, “Role of CD8+ CD25+ Foxp3+ regulatory T cells in multiple sclerosis,” Annals of Neurology, vol. 67, no. 5, pp. 625–638, 2010. View at Publisher · View at Google Scholar · View at Scopus
  29. A. Ueno, S. Cho, L. Cheng et al., “Transient upregulation of indoleamine 2,3-dioxygenase in dendritic cells by human chorionic gonadotropin downregulates autoimmune diabetes,” Diabetes, vol. 56, no. 6, pp. 1686–1693, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. A. M. Wolf, D. Wolf, H. Rumpold et al., “Overexpression of indoleamine 2,3-dioxygenase in human inflammatory bowel disease,” Clinical Immunology, vol. 113, no. 1, pp. 47–55, 2004. View at Publisher · View at Google Scholar · View at Scopus
  31. L. Zhou, H. Chen, Q. Wen, and Y. Zhang, “Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease,” European Journal of Gastroenterology & Hepatology, vol. 24, pp. 695–701, 2012. View at Publisher · View at Google Scholar · View at Scopus
  32. A. Dzionek, A. Fuchs, P. Schmidt et al., “BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood,” Journal of Immunology, vol. 165, no. 11, pp. 6037–6046, 2000. View at Google Scholar · View at Scopus
  33. U. Grohmann, F. Fallarino, R. Bianchi et al., “Il-6 inhibits the tolerogenic function of CD8α+ dendritic cells expressing indoleamine 2,3-dioxygenase,” Journal of Immunology, vol. 167, no. 2, pp. 708–714, 2001. View at Google Scholar · View at Scopus
  34. C. Orabona, P. Puccetti, C. Vacca et al., “Toward the identification of a tolerogenic signature in IDO-competent dendritic cells,” Blood, vol. 107, no. 7, pp. 2846–2854, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. W. Cao, “Molecular characterization of human plasmacytoid dendritic cells,” Journal of Clinical Immunology, vol. 29, no. 3, pp. 257–264, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Popov and J. L. Schultze, “IDO-expressing regulatory dendritic cells in cancer and chronic infection,” Journal of Molecular Medicine, vol. 86, no. 2, pp. 145–160, 2008. View at Publisher · View at Google Scholar · View at Scopus
  37. A. K. Manlapat, D. J. Kahler, P. R. Chandler, D. H. Munn, and A. L. Mellor, “Cell-autonomous control of interferon type I expression by indoleamine 2, 3-dioxygenase in regulatory CD19+ dendritic cells,” European Journal of Immunology, vol. 37, no. 4, pp. 1064–1071, 2007. View at Publisher · View at Google Scholar · View at Scopus
  38. W. Chen, X. Liang, A. J. Peterson, D. H. Munn, and B. R. Blazar, “The indoleamine 2,3-dioxygenase pathway is essential for human plasmacytoid dendritic cell-induced adaptive T regulatory cell generation,” Journal of Immunology, vol. 181, no. 8, pp. 5396–5404, 2008. View at Google Scholar · View at Scopus
  39. Á. González, N. Varo, E. Alegre, A. Díaz, and I. Melero, “Immunosuppression routed via the kynurenine pathway: a biochemical and pathophysiologic approach,” Advances in Clinical Chemistry, vol. 45, pp. 155–197, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. F. Fallarino, U. Grohmann, S. You et al., “Tryptophan catabolism generates autoimmune-preventive regulatory T cells,” Transplant Immunology, vol. 17, no. 1, pp. 58–60, 2006. View at Publisher · View at Google Scholar · View at Scopus
  41. S. Oertelt-Prigione, T. Mao, C. Selmi et al., “Impaired indoleamine 2,3-dioxygenase production contributes to the development of autoimmunity in primary biliary cirrhosis,” Autoimmunity, vol. 41, no. 1, pp. 92–99, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Lande, E. Giacomini, B. Serafini et al., “Characterization and recruitment of plasmacytoid dendritic cells in synovial fluid and tissue of patients with chronic inflammatory arthritis,” Journal of Immunology, vol. 173, no. 4, pp. 2815–2824, 2004. View at Google Scholar · View at Scopus